Introduction
============

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related deaths worldwide. Its prevalence is particularly high in East Asia, including countries such as China, Japan and Korea ([@b1-ijo-41-05-1675]). The prognosis of GC depends on the stage of diagnosis, as an early gastric cancer (EGC) or advanced gastric cancer (AGC) ([@b2-ijo-41-05-1675]). Despite the surgical advances that have improved long-term survival of GC patients ([@b3-ijo-41-05-1675],[@b4-ijo-41-05-1675]), molecular understanding of, as well as novel molecular biomarkers for, the condition is still urgently required for EGC, as EGC may progress towards AGC ([@b2-ijo-41-05-1675]).

To address this, several microarray analyses in GC have been performed and have identified gene expression patterns that may be useful in the prognosis and diagnosis of the cancer ([@b5-ijo-41-05-1675],[@b6-ijo-41-05-1675]); however, these approaches did not consider the different stages or subtypes of GC. Recent studies that did consider stage differences ([@b2-ijo-41-05-1675],[@b7-ijo-41-05-1675],[@b8-ijo-41-05-1675]) did not reveal the multiple phenotypes underlining EGC, because their primary aim was to study a handful of gene sets, which differentiate the stage differences. Accordingly, we further explored the various hidden phenotypes, functions and pathways in EGC by using an integrative systematic bioinformatics approach.

Here, we focus on molecular understanding of EGC-specific expression patterns gained by employing a systematic approach, including function and pathway, as well as cross-experiment analyses of 27 pairs of EGC tissues and their normal counterparts. Interestingly, the function and pathway analyses show that the upregulated genes in EGC tissues correlate with cell migration and metastasis, events typical of late-stage cancer. In addition, we propose a novel association between EGC and estrogen receptor α (ERα)-negative breast cancer that was indicated by cross-experiment analysis, and which enables us to identify various associated phenotypes.

Materials and methods
=====================

Patients and samples
--------------------

Tissue samples were prospectively collected from patients who underwent gastric surgery or gastroscopy at the National Cancer Center (NCC) Hospital between 2008 and 2009. All tissues were obtained according to the protocols approved by the Institutional Review Board, NCC for the human subject guideline of NCC (NCCNCS-08-127) that is in accordance with the principles of the Declaration of Helsinki. The samples were obtained by endoscopic biopsies from gastric cancer patients who gave informed consent to the protocol. The samples were stored at --80°C. The clinical and pathological features of the patients are listed in [Table I](#t1-ijo-41-05-1675){ref-type="table"}.

RNA extraction
--------------

Total RNA was extracted from gastric cancer and adjacent normal tissues from EGC patients using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), followed by purification of the RNA using Qiagen RNeasy mini kit columns (Valencia, CA, USA) according to the manufacturer's instructions. RNA quality was evaluated using the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and concentration measured by Nanodrop 1000 (Thermo Scientific, Wilmington, DE, USA). Only RNAs showing distinct 18S/28S ribosomal peak ratios of 1.5--2.0 in the Bioanalyzer (Agilent Technologies) and 260/280 ratios of 1.8--2.1 in the Nanodrop (Thermo Scientific) analyses were accepted for further analysis.

Microarray analysis and data processing
---------------------------------------

Genome-wide gene expression was analyzed in the 27-paired EGC tissue samples using Affymetrix GeneChip Human Exon1.0 ST Array (Santa Clara, CA, USA). Target preparation and microarray processing procedures were carried out as described in the manufacturer's instructions, and raw data were deposited in the NCBI Gene Expression Omnibus (GSE30727). The data were preprocessed by a default robust multi-array average (RMA) method implemented in the Bioconductor ([www.bioconductor.org](www.bioconductor.org)) 'oligo' package. The differentially expressed genes between EGC tissues and adjacent non-cancerous gastric tissues (i.e., the up- and downregulated genes in EGC) were filtered by a fold-change cut-off of 1.5 and a P-value cut-off of 0.05.

Functional/pathway enrichment analysis and cross-experimental analysis
----------------------------------------------------------------------

We downloaded a Gene Ontology (GO) annotation file (gene_association.goa_human) and an ontology file (gene_ontology_ext.obo) from [www.geneontology.org](www.geneontology.org), as recommended by the BiNGO tutorial ([@b9-ijo-41-05-1675]). In the BiNGO analysis, all options, except for filtering the IEA code, were set at default values. The false discovery rate (FDR) cut-off was 0.05. DAVID v6.7 software (<http://david.abcc.ncifcrf.gov/>) was used to summarize the over-representation of the KEGG pathways ([@b10-ijo-41-05-1675]). The gene expression signatures of up- or downregulated genes in EGC were analyzed using the L2L microarray analysis tool (<http://depts.washington.edu/l2l/>) ([@b11-ijo-41-05-1675]).

Reverse transcription PCR
-------------------------

Two micrograms of total RNA were reverse transcribed with Superscript III reverse transcriptase (Invitrogen). Reverse transcription PCR (RT-PCR) was performed using 5 ng cDNA for 1 cycle at 94°C for 2 min, followed by 32--35 cycles of 94°C for 20 sec, 60°C for 40 sec and 72°C for 30 sec, using gene-specific primers ([Table II](#t2-ijo-41-05-1675){ref-type="table"}). Gene expression levels were analyzed by gel electrophoresis.

Hierarchical clustering
-----------------------

Independent additional cancer datasets were obtained from NCBI GEO ([www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)) and EBI ArrayExpress ([www.ebi.ac.uk/arrayexpress](www.ebi.ac.uk/arrayexpress)): GSE19536 for ERα-negative breast cancers ([@b12-ijo-41-05-1675]), and the E-MTAB-62 dataset for Ewing's sarcoma, bladder cancer, small cell lung cancer and LNCaP prostate cancer cell lines ([@b13-ijo-41-05-1675]). The up- and downregulated genes in the EGC tissues were compared with these 5 cancer types. We transformed the expression of all our EGC tissue samples, GSE19536 and E-MTAB-62, into standard scores (z-scores), and then performed hierarchical clustering for the 6 cancers.

Results
=======

Genome-wide expression analysis
-------------------------------

We selected differentially expressed genes (i.e., up- and downregulated genes) from the 27 pairs of EGC tissue and their adjacent normal tissue. The P-value cut-off of 0.05 in t-tests, and the fold-change cut-off of 1.5 or 1/1.5 for up- and downregulated genes, respectively, was used for selection. We identified 556 upregulated genes and 417 downregulated genes. The differentially expressed genes were then fed into function, pathway and cross-experiment analyses to acquire a deeper understanding of the molecular basis of EGC.

Functional enrichment analysis
------------------------------

The BiNGO plug-in on the Cytoscape platform (<http://www.cytoscape.org/>) was used to explore the molecular function and biological processes in GO.

The functions of the upregulated genes of EGC tissues were significantly associated with C-X-C and other chemokine-related signaling, interleukin-8 binding, growth factor binding, collagen binding, and the extracellular matrix (ECM) ([Fig. 1A](#f1-ijo-41-05-1675){ref-type="fig"}). Moreover, the biological processes involved in the upregulated genes in the EGC tissues were strongly related to cell proliferation, mitosis, apoptosis and cell-matrix adhesion ([Fig. 1B](#f1-ijo-41-05-1675){ref-type="fig"}). Additionally, wound healing terms, cell migration terms and cell motility terms were also listed in the upregulated genes with statistical significance ([Table III](#t3-ijo-41-05-1675){ref-type="table"}). Since cell migration, cell motility and wound healing are typically observed in late-stage, metastatic cancer, this may indicate that EGC tissues could possess intrinsic aggressiveness, despite their early detection. Conversely, the downregulated genes were strongly linked to oxidoreductase activity (e.g., oxidoreductase activity acting on the CH or CH2 groups, quinones) in GO molecular function ([Fig. 1C](#f1-ijo-41-05-1675){ref-type="fig"}). Furthermore, the downregulated genes were enriched in various terms related to metabolic processes (e.g., flavone and flavonoid metabolic pathways) in GO biological processes ([Fig. 1D](#f1-ijo-41-05-1675){ref-type="fig"}). The GO terms of the downregulated genes clearly indicate dysregulation of metabolism in EGC, which is one of the emerging cancer hallmarks ([@b14-ijo-41-05-1675]).

Pathway enrichment analysis
---------------------------

The DAVID tool (<http://david.abcc.ncifcrf.gov/>) was used to inspect the KEGG biological pathways associated with the differently expressed genes in EGC.

The upregulated genes in EGC tissues were intrinsically associated with cytokine-cytokine receptor interactions, ECM-receptor interactions, the cell cycle, hematopoietic cell lineage and Toll-like receptor signaling pathways ([Table IV](#t4-ijo-41-05-1675){ref-type="table"}). In addition, focal adhesion and cell adhesion molecule pathways were highlighted. Thus, similar to the functional enrichment analysis, upregulated pathways in these tumor tissues suggest a strong potential for cell motility and metastasis, despite early detection. In contrast, the downregulated genes in the EGC tissues were strongly associated with xenobiotics-, drug-, retinol-, starch- and sucrose-related metabolism, steroid hormone biosynthesis, as well as pentose and glucuronate interconversion pathways ([Table IV](#t4-ijo-41-05-1675){ref-type="table"}).

The expression of MMPs in EGC tissue
------------------------------------

Our functional and pathway analyses demonstrated that the significantly upregulated genes in EGC tissues are associated with cell migration and metastasis, events typical of late-stage cancer. To verify our findings, we further analyzed the expression pattern of matrix metalloproteinases (MMPs), which are well known cell migration-related genes. MMPs are also known to play critical roles in the regulation of cell invasion by ECM proteolysis, as well as by processing cytokine precursors in the chemokine network.

We analyzed the expression pattern of 7 MMPs (MMP1, −3, −7, −9, −10, −12 and −13) within the upregulated gene data in EGC tissues. As expected, and consistent with the microarray data where MMPs were upregulated 1.56- to 8.68-fold ([Fig. 2A](#f2-ijo-41-05-1675){ref-type="fig"}), RT-PCR indicated that MMP mRNA expression was highly upregulated in the patients' EGC tissues ([Fig. 2B](#f2-ijo-41-05-1675){ref-type="fig"}).

Cross-experimental analysis
---------------------------

In order to investigate similar molecular signatures between EGC and other cancer types, we compared our data of differentially expressed genes with a public gene expression signature warehouse, L2L. This revealed that the upregulated genes in EGC most significantly correlated with the gene expression signature of ERα-negative breast cancer ([Table V](#t5-ijo-41-05-1675){ref-type="table"}). As summarized in [Table V](#t5-ijo-41-05-1675){ref-type="table"}, the upregulated genes in EGC were also similar to the gene expression signature related to an undifferentiated cancer status (cancer_undifferentiated_meta_up: 69 genes commonly upregulated in undifferentiated cancer relative to well-differentiated cancer, from a meta-analysis of the OncoMine gene expression database), stemness (stemcell_embryonic_up: enriched in mouse embryonic stem cells, compared to differentiated brain and bone marrow cells) and survival (dox_resist_gastric_up: upregulated in gastric cancer cell lines resistant to doxorubicin, compared to parent chemosensitive lines). Together, the EGC tissues reflect various facets of cancer-related phenotypes, viz., strong survival, stem-like and morphology.

The same L2L analysis was applied to the downregulated genes in EGC ([Table V](#t5-ijo-41-05-1675){ref-type="table"}). Interestingly, epigenetic-related cancer gene expression signature terms (5azac_hepg2_up and 5azac-tsa_hepg2_up in [Table V](#t5-ijo-41-05-1675){ref-type="table"}) were highly ranked. This suggests that global alterations in DNA methylation and histone modification occur in EGCs, as it does in other cancers.

Hierarchical clustering of the EGC tissues and other cancers
------------------------------------------------------------

To validate the result of the L2L analysis showing a relationship between EGC and ERα-negative breast cancer, we performed a hierarchical clustering analysis. The expression datasets of the differently expressed genes in EGC (556 upregulated gene symbols and 417 downregulated gene symbols), ERα-negative breast cancer and 4 additional cancers (small cell lung cancer, LNCaP prostate cancer cell lines, bladder cancer and Ewing sarcoma) were used in an unsupervised hierarchical clustering analysis. As in the L2L analysis, the results indicated that EGC correlated most closely with the ERα-negative cancer than with the other 4 cancers ([Fig. 3](#f3-ijo-41-05-1675){ref-type="fig"}).

When we inspected the expression levels (z-scores) of the 7 MMP genes ([Fig. 4](#f4-ijo-41-05-1675){ref-type="fig"}), the results indicated that the ERα-negative cancer, above all other observed cancers, showed the most similar expression patterns for the 7 MMPs. Overall, the hierarchical clustering was consistent with the cross-experimental analysis and strongly supported the molecular similarity between EGC and ERα-negative breast cancer in terms of carcinogenesis.

Discussion
==========

We analyzed the microarray data generated from pairs of tumor tissue and their adjacent non-cancerous tissue, obtained from 27 EGC patients. The gene expression data were subjected to functional and pathway analyses, as well as gene expression signature comparison (cross-experiment analysis). This led to 2 novel findings: i) the functional and pathway analyses suggested that metastasis-related biological processes may already be highly expressed even in the early stage of gastric cancer, and ii) the gene expression pattern of EGC is closely aligned to that of ERα-negative breast cancer.

We also compared the differentially expressed genes in our EGC tissues with other 3 previously published gene expression studies ([@b2-ijo-41-05-1675],[@b7-ijo-41-05-1675],[@b8-ijo-41-05-1675]). We found that the upregulated genes in our study significantly overlapped with the upregulated genes in the EGC groups of the 3 earlier studies ([@b2-ijo-41-05-1675],[@b7-ijo-41-05-1675],[@b8-ijo-41-05-1675]), under a randomization model ([Table VI](#t6-ijo-41-05-1675){ref-type="table"}). Recently, Vecchi *et al* suggested a carcinogenesis model ([@b2-ijo-41-05-1675]) in which the transition from normal mucosa to EGC is accompanied by cell cycle upregulation; our pathway analysis results (hsa04110, cell cycle in [Table IV](#t4-ijo-41-05-1675){ref-type="table"}) is consistent with this model. Interestingly, AGC functions (cell migration-and ECM-related functions), suggested by the Vecchi model were also revealed in our EGC data, again indicating that EGC actually harbors gene expression events that are usually observed in the later stages of cancer, such as AGC.

Based on our functional and pathway analyses, the upregulated genes in the EGC tissues were highly enriched for genes involved in cell proliferation, chemokine/growth factor signaling and cell migration. The computational implication is, in fact, closely related to MMP activity, as MMP substrates include growth factor/chemokine precursors and E-cadherin ([@b15-ijo-41-05-1675],[@b16-ijo-41-05-1675]). We validated the upregulation of the 7 MMPs in the EGC tissues by RT-PCR. This result suggests that the activation of multiple MMPs may be involved in the early stage of cancer. The suggestion is noteworthy, when considering that the roles of multiple MMPs were mainly reported in late-stage gastric cancer ([@b2-ijo-41-05-1675],[@b17-ijo-41-05-1675]). It is also interesting to note that 6 (MMP1, −3, −7, −10, −12 and −13) of the 7 MMPs are clustered at 11q22, implying that epigenetic events could be involved in the upregulation of the clustered MMPs ([@b18-ijo-41-05-1675]).

Additionally, we found that the gene expression pattern in EGC tissues resembles the pattern of the ERα-negative breast cancer transcriptome. Since ERα-negative breast cancer clusters with EGC ([Fig. 3](#f3-ijo-41-05-1675){ref-type="fig"}), the similarity suggests that these two cancers may share common molecular features. Recent breast cancer studies ([@b19-ijo-41-05-1675],[@b20-ijo-41-05-1675]) reported that high expression of cyclooygenase-2 (Cox-2), encoded by PTGS2, is associated with poor survival in ERα-negative breast cancer patients, when compared to ERα-positive breast cancers. Interestingly, Cox-2 is highly involved in the inflammation-associated carcinogenesis of the gastrointestinal tract. In particular,

*H. pylori*-infected gastric epithelial cells can experience malignant transformation via Toll-like receptor (TLR) signaling that induces Cox-2, followed by activation of cell proliferation ([@b21-ijo-41-05-1675]). In fact, our pathway analysis in EGC showed upregulation of the KEGG TLR signaling pathway and cell cycle pathway ([Table IV](#t4-ijo-41-05-1675){ref-type="table"}, [Fig. 5](#f5-ijo-41-05-1675){ref-type="fig"}). Our EGC also showed a markedly increased expression of PTGS2 (5.74-fold-change). Thus, the similarity between EGC and ERα-negative breast cancer may come from identical subsets of immune response-related signaling between the microenvironments of the tumors.

In conclusion, we have analyzed the differentially expressed genes in EGC patients using an integrative systematic approach. We found that genes highly expressed in EGC are involved in cell migration- and metastasis-related functions typically observed in late-stage cancer. Also, EGC may be intrinsically similar to ERα-negative breast cancer, by sharing immune-related signaling events, which is further dissected in both cancer types. The functional roles of the downregulated genes in EGC carcinogenesis remain to be elucidated in future.

This study was funded by Intramural Research Grants of the National Cancer Center (NCC 1210460-1).

![The GO analysis by BiNGO. (A) The upregulated molecular functions in EGC tissues. (B) The upregulated biological process in EGC tissues. (C) The downregulated molecular functions in EGC tissues. (D) The downregulated biological process in EGC tissues. The Information is presented as a percentage of x/n (x, the number of genes in a cluster annotated for a certain GO term; n, the number of genes in the reference set annotated for a certain GO term).](IJO-41-05-1675-g00){#f1-ijo-41-05-1675}

![The expression of MMPs in EGC tissues. (A) Expression levels of MMPs genes in microarray data. The vertical axis represents fold-change of the cancer tissues over normal tissues. (B) mRNA expression of MMPs using RT-PCR. Three pairs of non-cancerous and tumor tissues from the microarray analysis were used. (N, adjacent non-cancerous gastric tissue; T, EGC tissue).](IJO-41-05-1675-g01){#f2-ijo-41-05-1675}

![Hierarchical clustering. Genes up- or downregulated in EGC as well as 5 independent cancer types were used in the hierarchical clustering analysis. Each cancer type is presented with the following column side-bars: EGC (brown), ERα-negative breast cancers (orange), bladder cancer (grey), Ewing sarcoma (black), small cell lung cancers (yellow) and LNCaP prostate cancer cell lines (blue). Seven MMP genes are presented with row side-bars.](IJO-41-05-1675-g02){#f3-ijo-41-05-1675}
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![The upregulated genes belonging to the KEGG TLR signaling pathway (A) and cell cycle pathway (B) in our EGC tissues.](IJO-41-05-1675-g04){#f5-ijo-41-05-1675}

###### 

Clinical features for 27 patients with gastric cancer.

  Characteristics                                             No. of patients[^a^](#tfn1-ijo-41-05-1675){ref-type="table-fn"}
  ----------------------------------------------------------- -----------------------------------------------------------------
  Total                                                       27
    Male                                                      20
    Female                                                    7
  Age at diagnosis (years)                                    
    Range                                                     41--78
    Mean ± SD                                                 60.3±11.2
  TNM stage[^b^](#tfn2-ijo-41-05-1675){ref-type="table-fn"}   
    T classification                                          
      T1                                                      17
      T2                                                      10
      T3                                                      0
    N classification                                          
      N0                                                      13
      N1                                                      10
      N2                                                      2
      N3                                                      2
    M classification                                          
      M0                                                      27
      M1                                                      0
  Lauren classification                                       
    Intestinal                                                12
    Diffuse                                                   7
    Mixed                                                     6
    NA[^c^](#tfn3-ijo-41-05-1675){ref-type="table-fn"}        2

The 27 patient samples were used in microarray analysis.

UICC/AJCC 6th edition.

Not available of Lauren classification.

###### 

The primer sequences used in RT-PCR.

  Primer ID   Sequence (5′→3′)
  ----------- ----------------------
  MMP1-F      CTGGAATTGGCCACAAAGTT
  MMP1-R      CCTTCTTTGGACTCACACCA
  MMP3-F      CCCTGGGTCTCTTTCACTCA
  MMP3-R      TCAAAGGACAAAGCAGGATC
  MMP7-F      CGGATGGTAGCAGTCTAGGG
  MMP7-R      TGAATGGATGTTCTGCCTGA
  MMP9-F      GGGAAGATGCTGCTGTTCA
  MMP9-R      TCAACTCACTCCGGGAACTC
  MMP10-F     GGCTCTTTCACTCAGCCAAC
  MMP10-R     TCCCGAAGGAACAGATTTTG
  MMP12-F     CCTTCAGCCAGAAGAACCTG
  MMP12-R     ACACATTTCGCCTCTCTGCT
  MMP13-F     TTGAGCTGGACTCATTGTCG
  MMP13-R     GGAGCCTCTCAGTCATGGAG
  GAPDH-F     TGCACCACCAACTGCTTA
  GAPDH-R     GGATGCAGGGATGATGTTC

###### 

The GO biological process terms associated with genes upregulated in gastric cancer tissues, relating to wound healing, cell migration and cell motility.

  GO-ID        P-value    Corrected P-value[^a^](#tfn4-ijo-41-05-1675){ref-type="table-fn"}   x[^b^](#tfn5-ijo-41-05-1675){ref-type="table-fn"}   n[^c^](#tfn6-ijo-41-05-1675){ref-type="table-fn"}   x/n (%)   Description
  ------------ ---------- ------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------- --------- ---------------------------------------------------
  GO:0014910   1.54E-03   1.86E-02                                                            4                                                   14                                                  29        Regulation of smooth muscle cell migration
  GO:0061041   5.41E-07   3.15E-05                                                            11                                                  44                                                  25        Regulation of wound healing
  GO:0010595   4.41E-03   4.25E-02                                                            5                                                   29                                                  17        Positive regulation of endothelial cell migration
  GO:0030335   3.69E-07   2.38E-05                                                            18                                                  116                                                 16        Positive regulation of cell migration
  GO:2000147   3.69E-07   2.38E-05                                                            18                                                  116                                                 16        Positive regulation of cell motility
  GO:0030334   9.12E-07   4.44E-05                                                            23                                                  190                                                 12        Regulation of cell migration
  GO:2000145   1.44E-06   6.12E-05                                                            23                                                  195                                                 12        Regulation of cell motility
  GO:0048870   9.75E-10   1.81E-07                                                            38                                                  330                                                 12        Cell motility
  GO:0042060   1.04E-10   3.09E-08                                                            50                                                  485                                                 10        Wound healing

Multiple comparison corrected P-value.

The number of the input genes annotated to a certain GO term.

The number of genes in the reference set annotated to a certain GO term.

###### 

Pathway enrichment analysis for up- and downregulated genes in gastric cancer tissues.

  Input genes              Pathways                                                 Count[^a^](#tfn7-ijo-41-05-1675){ref-type="table-fn"}   P-value
  ------------------------ -------------------------------------------------------- ------------------------------------------------------- -----------
  Upregulated pathways     hsa04060, cytokine-cytokine receptor interaction         38                                                      3.61.E-11
                           hsa04512, ECM-receptor interaction                       17                                                      3.16.E-07
                           hsa04110, cell cycle                                     19                                                      4.21.E-06
                           hsa04640, hematopoietic cell lineage                     13                                                      2.40.E-04
                           hsa04620, Toll-like receptor signaling pathway           14                                                      3.02.E-04
                           hsa04062, chemokine signaling pathway                    20                                                      3.18.E-04
                           hsa04610, complement and coagulation cascades            11                                                      5.85.E-04
                           hsa04510, focal adhesion                                 19                                                      2.00.E-03
                           hsa04115, p53 signaling pathway                          10                                                      2.11.E-03
                           hsa04514, cell adhesion molecules (CAMs)                 14                                                      3.72.E-03
                           hsa05222, small cell lung cancer                         10                                                      8.79.E-03
                           hsa04670, leukocyte transendothelial migration           12                                                      1.11.E-02
                           hsa05020, prion diseases                                 6                                                       1.51.E-02
                           hsa04621, NOD-like receptor signaling pathway            8                                                       1.53.E-02
                           hsa05200, pathways in cancer                             23                                                      2.09.E-02
                           hsa05332, graft vs. host disease                         6                                                       2.34.E-02
                           hsa05322, systemic lupus erythematosus                   10                                                      2.40.E-02
                           hsa05219, bladder cancer                                 6                                                       3.13.E-02
                           hsa04114, oocyte meiosis                                 10                                                      4.32.E-02
                           hsa04650, natural killer cell mediated cytotoxicity      11                                                      5.53.E-02
                           hsa04142, lysosome                                       10                                                      5.97.E-02
                           hsa04630, Jak-STAT signaling pathway                     12                                                      6.43.E-02
                           hsa04914, progesterone-mediated oocyte maturation        8                                                       7.17.E-02
  Downregulated pathways   hsa00980, metabolism of xenobiotics by cytochrome P450   22                                                      3.33.E-18
                           hsa00982, drug metabolism                                22                                                      7.29.E-18
                           hsa00830, retinol metabolism                             19                                                      2.76.E-15
                           hsa00140, steroid hormone biosynthesis                   13                                                      3.63.E-09
                           hsa00500, starch and sucrose metabolism                  11                                                      2.00.E-07
                           hsa00040, pentose and glucuronate interconversions       8                                                       3.57.E-07
                           hsa00590, arachidonic acid metabolism                    12                                                      3.95.E-07
                           hsa00983, drug metabolism                                10                                                      2.69.E-06
                           hsa00053, ascorbate and aldarate metabolism              7                                                       5.02.E-06
                           hsa00591, linoleic acid metabolism                       8                                                       1.04.E-05
                           hsa00860, porphyrin and chlorophyll metabolism           8                                                       3.32.E-05
                           hsa00010, glycolysis/gluconeogenesis                     10                                                      4.64.E-05
                           hsa00150, androgen and estrogen metabolism               8                                                       7.27.E-05
                           hsa03320, PPAR signaling pathway                         7                                                       1.41.E-02
                           hsa00051, fructose and mannose metabolism                5                                                       1.59.E-02
                           hsa00330, arginine and proline metabolism                6                                                       1.78.E-02
                           hsa00071, fatty acid metabolism                          5                                                       2.74.E-02
                           hsa00030, pentose phosphate pathway                      4                                                       3.42.E-02
                           hsa00350, tyrosine metabolism                            5                                                       3.72.E-02
                           hsa00920, sulfur metabolism                              3                                                       4.53.E-02
                           hsa00340, histidine metabolism                           4                                                       5.00.E-02
                           hsa00480, glutathione metabolism                         5                                                       5.54.E-02

Count represents the number of input genes assigned to the KEGG pathway.

###### 

The selected L2L results of genes up- or downregulated in early gastric cancer.

  Input genes                                         L2L term (PubMed ID)                         Description                                                                                                                                                                                        x[^a^](#tfn8-ijo-41-05-1675){ref-type="table-fn"}/n[^b^](#tfn9-ijo-41-05-1675){ref-type="table-fn"}   Binomial P-value
  --------------------------------------------------- -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------
  Upregulated genes in the gastric cancer tissues     brca_er_neg (11823860)                       Genes whose expression is consistently negatively correlated with the gastric cancer tissues estrogen receptor status in breast cancer - higher expression is associated with ER-negative tumors   145/996                                                                                               7.50E-95
                                                      cancer_undifferentiated_meta_up (15184677)   Sixty-nine genes commonly upregulated in undifferentiated cancer relative to well-differentiated cancer, from a meta-analysis of the OncoMine gene expression database                             25/69                                                                                                 2.21E-28
                                                      dox_resist_gastric_up (14734480)             Upregulated in gastric cancer cell lines resistant to doxorubicin, compared to parent chemosensitive lines                                                                                         17/48                                                                                                 1.44E-19
                                                      stemcell_embryonic_up (12228720)             Enriched in mouse embryonic stem cells, compared to differentiated brain and bone marrow cells                                                                                                     74/1350                                                                                               1.32E-21
  Downregulated genes in the gastric cancer tissues   5azac_hepg2_up (16854234)                    Upregulated in human hepatoma cells (HepG2) following 48 of treatment with 2.5 *μ*M 5-aza-2-deoxycytidine (5azaC)                                                                                  60/1311                                                                                               6.61E-20
                                                      5azac-tsa_hepg2_up (16854234)                Upregulated in human hepatoma cells (HepG2) following 24 h of treatment with 2.5 *μ*M 5-aza-2-deoxycytidine (5azaC) and 24 h of treatment with both 5azaC and 500 nM trichostatin A (TSA)          66/1619                                                                                               3.69E-19

The number of the input genes annotated to a L2L term.

The number of genes in the reference set annotated to a L2L term.

###### 

Comparisons with other GC sources in terms of upregulated EGC-related genes.

  Refs.                    EGC classification                                            n[^a^](#tfn10-ijo-41-05-1675){ref-type="table-fn"}   x[^b^](#tfn11-ijo-41-05-1675){ref-type="table-fn"}   Significance (P-value)[^c^](#tfn12-ijo-41-05-1675){ref-type="table-fn"}
  ------------------------ ------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------
  ([@b2-ijo-41-05-1675])   \-                                                            488                                                  83                                                   \<2.2E-16
  ([@b7-ijo-41-05-1675])   Well-differentiated (WD) and moderately differentiated (MD)   170                                                  62                                                   \<2.2E-16
  ([@b8-ijo-41-05-1675])   AJCC staging I and II (TNM staging)                           118                                                  15                                                   1.601E-06

The number of upregulated genes in the cancer according to the references.

The number of common upregulated genes (intersection) between the references and ours.

The significance of the intersections between our EGC upregulated genes and the studies were calculated. Fisher's exact test, based on the randomization model, was used to obtain the P-values of the intersections from a hyper-geometric distribution. The smaller the P-value, the more significant the agreement between the previous study and our EGC study. The total number of gene symbols used in the Fisher's exact test is 19,211 (HUGO Gene Nomenclature Committee).

[^1]: Contributed equally
